Publication: Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry.
dc.contributor.author | Fernández-Fabrellas, Estrella | |
dc.contributor.author | Molina-Molina, María | |
dc.contributor.author | Soriano, Joan B | |
dc.contributor.author | Portal, José Antonio Rodríguez | |
dc.contributor.author | Ancochea, Julio | |
dc.contributor.author | Valenzuela, Claudia | |
dc.contributor.author | Xaubet, Antoni | |
dc.contributor.author | SEPAR-IPF National Registry | |
dc.date.accessioned | 2023-01-25T13:35:13Z | |
dc.date.available | 2023-01-25T13:35:13Z | |
dc.date.issued | 2019-06-17 | |
dc.description.abstract | Little is known on the characteristics of patients diagnosed with idiopathic pulmonary fibrosis (IPF) in Spain. We aimed to characterize the demographic and clinical profile of IPF patients included in the IPF National Registry of the Spanish Respiratory Society (SEPAR). This is a prospective, observational, multicentre and nationwide study that involved 608 IPF patients included in the SEPAR IPF Registry up to June 27th, 2017, and who received any treatment for their disease. IPF patients were predominantly males, ex-smokers, and aged in their 70s, similar to other registries. Upon inclusion, mean ± SD predicted forced vital capacity was 77.6% ± 19.4, diffusing capacity for carbon monoxide was 48.5% ± 17.7, and the 6-min walk distance was 423.5 m ± 110.4. The diagnosis was mainly established on results from the high-resolution computed tomography in the proper clinical context (55.0% of patients), while 21.2% of patients required invasive procedures (surgical lung biopsy) for definitive diagnosis. Anti-fibrotic treatment was prescribed in 69.4% of cases, 51.5% pirfenidone and 17.9% nintedanib, overall with a good safety profile. The SEPAR IPF Registry should help to further characterize current characteristics and future trends of IPF patients in Spain and compare/pool them with other registries and cohorts. | |
dc.identifier.doi | 10.1186/s12931-019-1084-0 | |
dc.identifier.essn | 1465-993X | |
dc.identifier.pmc | PMC6580511 | |
dc.identifier.pmid | 31208406 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580511/pdf | |
dc.identifier.unpaywallURL | https://respiratory-research.biomedcentral.com/counter/pdf/10.1186/s12931-019-1084-0 | |
dc.identifier.uri | http://hdl.handle.net/10668/14133 | |
dc.issue.number | 1 | |
dc.journal.title | Respiratory research | |
dc.journal.titleabbreviation | Respir Res | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Virgen de las Nieves | |
dc.organization | Área de Gestión Sanitaria Sur de Sevilla | |
dc.organization | Hospital Universitario Virgen del Rocío | |
dc.organization | AGS - Sur de Sevilla | |
dc.page.number | 127 | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Multicenter Study | |
dc.pubmedtype | Observational Study | |
dc.rights | Attribution 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Anti-fibrotic treatment | |
dc.subject | Idiopathic pulmonary fibrosis | |
dc.subject | National registry | |
dc.subject | SEPAR | |
dc.subject | Spain | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Anti-Inflammatory Agents, Non-Steroidal | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Idiopathic Pulmonary Fibrosis | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Prospective Studies | |
dc.subject.mesh | Pyridones | |
dc.subject.mesh | Registries | |
dc.subject.mesh | Retrospective Studies | |
dc.subject.mesh | Societies, Medical | |
dc.subject.mesh | Spain | |
dc.title | Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 20 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1